Janux Therapeutics, Inc. (JANX)
Last updated: 2026-10-20 09:34:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Janux Therapeutics, Inc. (JANX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.75, with a market capitalization of $1.01B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.12 to $35.34. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.01B | |
$16.61 | |
$71.71 | |
$5.65 | |
$16.51 | |
771.85K | |
847.69K | |
-- | |
$35.34 | |
$12.12 | |
-- | |
-- |
Janux Therapeutics, Inc. (JANX) Pre-Market Stock Price
Janux Therapeutics, Inc. (JANX) is trading at $16.19 in pre-market trading as of 2026-10-19 20:41:00, down 1.93% ($0.32) from the previous close of $16.51
Pre-market trading shows how investors are pricing JANX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Janux Therapeutics, Inc. (JANX) 7-Day Stock Price Change
Over the past seven days, Janux Therapeutics, Inc. (JANX) moved from $18.39 to $16.75, representing a decline of 8.91% ($1.64).
The stock traded between $16.19 and $19.18 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 801.91 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
JANX 52-Week Price Position
Position in Range: 19.9%
JANX is currently trading at $16.75, placing it 19.9% of the way from its 52-week low of $12.12 to its 52-week high of $35.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Janux Therapeutics, Inc. (JANX)?
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 113 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Janux Therapeutics, Inc. (JANX) Stock on MEXC
Eligible investors can buy real shares of Janux Therapeutics, Inc. (JANX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Janux Therapeutics, Inc. (JANX) stock price today?
2.Is JANX stock going up or down today?
3.What is JANX pre-market price?
4.What is JANX after-hours price?
5.Is JANX stock trading now?
6.Where does JANX sit relative to its 52-week high and low?
7.What sector is Janux Therapeutics, Inc. in?
8.What is Janux Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is JANX valued in terms of P/E ratio and EPS?
10.Does Janux Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
JANX Stock Calculator
Estimate the value between JANX shares and USD.
JANX Shares to USD
1.00 JANX shares = 16.752 USD
Calculations are estimates based on the latest available price and are for reference only.


